Integrating Hearing-Targeted Congenital Cytomegalovirus Follow-Up into Existing Newborn Screening Infrastructure: Georgia’s Experience

Congenital cytomegalovirus (cCMV) is the leading non-genetic cause of childhood sensorineural hearing loss. However, published descriptions of state-level approaches for integrating cCMV follow-up into existing Early Hearing Detection and Intervention (EHDI) and Newborn Blood Spot Screening (NBS) follow-up infrastructure are limited. In October 2024, hearing-targeted cCMV testing became required in Georgia through a change to the state’s rules and regulations. The Georgia Department of Public Health (DPH) developed a follow-up protocol built on three core components: cCMV was designated a notifiable condition, triggering electronic laboratory reporting (ELR) to DPH alongside provider and facility reporting requirements; medical follow-up for cCMV cases was integrated into the state’s existing NBS follow-up processes; and an audiologist-led protocol was established to facilitate timely diagnostic hearing evaluation and ongoing audiologic follow-up for confirmed cCMV cases. Between 10 October 2024 and 10 March 2026, DPH identified 103 newborns with an initial positive cCMV result. After excluding nine cases that did not enter the follow-up workflow at birth, 94 newborns were included in this analysis. Of these, 59 (62.8%) were laboratory-confirmed cCMV-positive, 33 (35.1%) were false positive, and 2 (2.1%) were presumptive positive. One newborn died before completing audiologic follow-up and was excluded from follow-up outcomes. Among the remaining 58 laboratory-confirmed cCMV cases requiring audiologic follow-up, 52 (89.7%) completed diagnostic Auditory Brainstem Response (ABR) evaluation and 6 (10.3%) were lost to follow-up; 14 of 52 (26.9%) evaluated newborns were diagnosed with sensorineural hearing loss (SNHL). This paper describes Georgia’s cCMV follow-up strategy and reports preliminary outcomes from the program’s first 18 months of implementation, offering an adaptable framework for integrating cCMV case follow-up and audiologic surveillance into existing state public health infrastructure.

Authors

Institutions

Publication Details

Journal
International Journal of Neonatal Screening
Published
2026-11-17
DOI
https://doi.org/10.3390/ijns12040101
Primary Topic
Cytomegalovirus and herpesvirus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrating Hearing-Targeted Congenital Cytomegalovirus Follow-Up into Existing Newborn Screening Infrastructure: Georgia’s Experience

Tracy Kavanaugh, Adrya Stembridge, Angela Wittenauer, Holly Juca et al.
3 links
International Journal of Neonatal Screening
Cytomegalovirus and herpesvirus research
article

Integrating Hearing-Targeted Congenital Cytomegalovirus Follow-Up into Existing Newborn Screening Infrastructure: Georgia’s Experience

Tracy Kavanaugh, Adrya Stembridge, Angela Wittenauer, Holly Juca, Melanie Morris, Michael Andrews, Michael Lo, Suzanne Caruthers
article en

Abstract

Congenital cytomegalovirus (cCMV) is the leading non-genetic cause of childhood sensorineural hearing loss. However, published descriptions of state-level approaches for integrating cCMV follow-up into existing Early Hearing Detection and Intervention (EHDI) and Newborn Blood Spot Screening (NBS) follow-up infrastructure are limited. In October 2024, hearing-targeted cCMV testing became required in Georgia through a change to the state’s rules and regulations. The Georgia Department of Public Health (DPH) developed a follow-up protocol built on three core components: cCMV was designated a notifiable condition, triggering electronic laboratory reporting (ELR) to DPH alongside provider and facility reporting requirements; medical follow-up for cCMV cases was integrated into the state’s existing NBS follow-up processes; and an audiologist-led protocol was established to facilitate timely diagnostic hearing evaluation and ongoing audiologic follow-up for confirmed cCMV cases. Between 10 October 2024 and 10 March 2026, DPH identified 103 newborns with an initial positive cCMV result. After excluding nine cases that did not enter the follow-up workflow at birth, 94 newborns were included in this analysis. Of these, 59 (62.8%) were laboratory-confirmed cCMV-positive, 33 (35.1%) were false positive, and 2 (2.1%) were presumptive positive. One newborn died before completing audiologic follow-up and was excluded from follow-up outcomes. Among the remaining 58 laboratory-confirmed cCMV cases requiring audiologic follow-up, 52 (89.7%) completed diagnostic Auditory Brainstem Response (ABR) evaluation and 6 (10.3%) were lost to follow-up; 14 of 52 (26.9%) evaluated newborns were diagnosed with sensorineural hearing loss (SNHL). This paper describes Georgia’s cCMV follow-up strategy and reports preliminary outcomes from the program’s first 18 months of implementation, offering an adaptable framework for integrating cCMV case follow-up and audiologic surveillance into existing state public health infrastructure.

International Journal of Neonatal ScreeningVol. 12(4)
Emory University (US), Georgia Department of Public Health (US)
Good health and well-being
Cytomegalovirus and herpesvirus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon